Evicenter
MarkdownMedical informationP&T meetings
Barzolvolimab (CDX-0159)

Chronic spontaneous urticaria

Launch
Not announced
Last updated
177 sources

Section 1 of 6

Terms and abbreviations

1 evidence topic · 0 sources

AbbreviationTerm
12W12 weeks
AAAAIAmerican Academy of Allergy, Asthma & Immunology
AAbsAutoantibodies
AADAmerican Academy of Dermatology
AASAngioedema Activity Score
AAS28Angioedema Activity Score 4-week sum score
AAS7Weekly Angioedema Activity Score
ACAAIAmerican College of Allergy, Asthma & Immunology
ACEAngiotensin-converting enzyme
ADAtopic dermatitis
ADAAntidrug antibodies
AE, AEsAdverse event; angioedema (in recurrent AE)
AECTAngioedema Control Test
AHFSAmerican Hospital Formulary Service
aiCSUAutoimmune chronic spontaneous urticaria
AIDsAutoimmune diseases
ANCAbsolute neutrophil count
ANCOVAAnalysis of covariance
ANOVAAnalysis of variance
APACAll Payer All Claims
A-PPAAAAI Practice Parameter Update 2014
ASSTAutologous serum skin test
aTPO, anti-TPOAnti-thyroid peroxidase (antibody)
AUCArea under the concentration-time curve; area under the receiver operating characteristic curve
BASOBasophil test
BATBasophil activation test
BHRABasophil histamine release assay
bIgETotal IgE before treatment (baseline)
BIMBudget impact model
BLBaseline
BLABiologics License Application
BMIBody mass index
BNFBritish National Formulary
BTKBruton's tyrosine kinase
C1Complement component 1
C1qComplement component 1q
CACalifornia
CAPSCryopyrin-associated periodic syndromes
CBCComplete blood count
CCComplete control
CDCeliac disease
CD117Cluster of differentiation 117 (KIT)
CD34Cluster of differentiation 34
CD63Cluster of differentiation 63
CDMClinformatics Data Mart
CDMOsContract development & manufacturing organizations
CDX-0158Celldex development code for the predecessor anti-KIT antibody of barzolvolimab, with an unmodified IgG1/κ backbone
CDX-0159Celldex development code for barzolvolimab
CENTRALCochrane Central Register of Controlled Trials
CFBChange from baseline
cGMPCurrent Good Manufacturing Practice
CH5050% hemolytic complement (total complement activity)
CHOChinese hamster ovary
CI, CIsConfidence interval
CI95%95% confidence interval
CIndU, CIndUs, CINDUChronic inducible urticaria
CIUChronic idiopathic urticaria
c-Kit, c-KITCellular KIT (KIT receptor tyrosine kinase)
c-Kitlc-Kit ligand (stem cell factor)
CLDXNasdaq ticker symbol of Celldex Therapeutics
CmaxMaximum serum concentration
ColdUCold urticaria
COVID-19Coronavirus disease 2019
COX-2Cyclooxygenase-2
CRComplete response
CrICredible interval
CRPC-reactive protein
CRSwNPChronic rhinosinusitis with nasal polyps
CsACyclosporine A
CSUChronic spontaneous urticaria
CSUaiTIIbChronic spontaneous urticaria of autoimmune type IIb
CTISClinical Trials Information System
CT-P39Celltrion development code for an omalizumab biosimilar
CUChronic urticaria
CU-Q2oLChronic Urticaria Quality of Life Questionnaire
CYP3A4Cytochrome P450 3A4
DALYsDisability-adjusted life years
DDDiagnostic delay
DiffDifference
diffDifferential (white blood cell count)
DLQIDermatology Life Quality Index
DPDrug Product
DSDrug Substance
DSQDysphagia Symptom Questionnaire
EAACIEuropean Academy of Allergy and Clinical Immunology
EADVEuropean Academy of Dermatology & Venereology
EAPCEstimated annual percentage change
EC50Half-maximal effective concentration
EDEmergency department
EHR, EHRsElectronic Health Record
EMBASEExcerpta Medica Database
EoEEosinophilic esophagitis
EQ-5D, EQ-5D-3LEuroQol 5-Dimension questionnaire; EuroQol 5-Dimension 3-Level questionnaire
EREFSEosinophilic Esophagitis Endoscopic Reference Score (endoscopic scoring of EoE-related inflammation & fibrosis)
ESRErythrocyte sedimentation rate
EUEuropean Union
FACAAIFellow of the American College of Allergy, Asthma and Immunology
FcFragment crystallizable (region of an antibody)
FcRnNeonatal Fc receptor
FcγRFc gamma receptor
FcεRI, FcϵRI, FcεR1High-affinity IgE receptor (Fc epsilon receptor I)
FDAFood and Drug Administration
FDLQIFamily Dermatology Life Quality Index
FU, FU1, FU2Follow-up; follow-up visit 1; follow-up visit 2
G2, G3, G4Grade 2, grade 3, grade 4
GAD-7Generalized Anxiety Disorder 7-item scale
GBDGlobal Burden of Disease
GDPGross domestic product
GLPGood Laboratory Practice
GRADEGrading of Recommendations Assessment, Development and Evaluation
H1Histamine type 1 (receptor)
H1-AH, H1-AHs, H1AHH1-antihistamine (H1AH: Type 1 antihistamine)
H2Histamine type 2 (receptor)
HAEHereditary angioedema
HCRUHealthcare resource utilization
HIVHuman immunodeficiency virus
HMC-1.2Human mast cell line 1, subclone 2
HRHazard ratio
HRQoLHealth-related quality of life
HRUHealth care resource utilization
HSSHives Severity Score
HSS7Weekly Hives Severity Score
huKIT-D4D5Membrane proximal dimerization domains (Ig 4 and 5) of human KIT
HVHealthy volunteers
I2I-squared statistic of heterogeneity
IC50Half-maximal inhibitory concentration
ICD-9, ICD-10International Classification of Diseases, version 9 and version 10
ICER, ICERsIncremental cost-effectiveness ratio
IgImmunoglobulin (immunoglobulin-like domain)
IgEImmunoglobulin E
IgGImmunoglobulin G
IgG1Immunoglobulin G1
IgG1κ, IgG1/κImmunoglobulin G1 kappa
IHCImmunohistochemistry
ILInterleukin
IL-4RaInterleukin-4 receptor alpha
ILC2Group 2 innate lymphoid cell
INNInternational nonproprietary name
IQRInterquartile range
ISSItch Severity Score
ISS7Weekly Itch Severity Score
IVIntravenous
JTFJoint Task Force (on Practice Parameters)
JTFPPJoint Task Force on Practice Parameters
KITMast/stem cell growth factor receptor KIT (receptor tyrosine kinase)
KITD816VKIT carrying the D816V substitution (aspartic acid to valine at codon 816)
LDLoading dose
LLoQLower limit of assay quantitation
LSLeast squares
LTELong-term extension
LTRALeukotriene receptor antagonist
mAbMonoclonal antibody
MADMultiple ascending doses
MC, MCsMast cell
MCDMean cost difference
MCIDMinimal clinically important difference
MCSMental Component Summary
MCTCMast cell containing tryptase and chymase
MDMean difference; Doctor of Medicine
MEDLINEMedical Literature Analysis and Retrieval System Online
MHMental health
MIDMinimal important difference
mITTModified intent-to-treat
MMRMMixed model for repeated measures
MRGPRX2Mas-related G-protein coupled receptor member X2
NASDAQNational Association of Securities Dealers Automated Quotations
NENot estimable
NHPNottingham Health Profile
NHWSNational Health and Wellness Survey
NICENational Institute for Health and Care Excellence
N.J., NJNew Jersey
nsAHNon-sedating H1-antihistamine
NSAIDsNonsteroidal anti-inflammatory drugs
OROdds ratio
OX40OX40 receptor (tumor necrosis factor receptor superfamily member 4)
OX40LOX40 ligand
PAFPlatelet activation factor
PatGAPatients Global Assessment
PCSPhysical Component Summary
PDPharmacodynamics
PGD2Prostaglandin D2
PHQ-9Patient Health Questionnaire 9-item
PhysGA, PhyGAPhysician Global Assessment
PKPharmacokinetics
PNPrurigo nodularis
PPP, PPP$Purchasing power parity; purchasing power parity dollars
PPPYPer patient per year
PPQProcess Performance Qualification
PROMsPatient-reported outcome measures
PsO, PSOPsoriasis
PTAPatent term adjustment
PTEPatent term extension
Q2WEvery 2 weeks
Q4Fourth quarter of a calendar year
Q4WEvery 4 weeks
Q4 WKEvery 4 weeks
Q8WEvery 8 weeks
Q8 WKEvery 8 weeks
QALY, QALYsQuality-adjusted life-year
QIDFour times daily
QoLQuality of life
RARheumatoid arthritis; recurrent angioedema (in the AECT validation quote)
RCT, RCTsRandomized controlled trial
RDRisk difference
RecARecurrent angioedema
ref-OMAReference omalizumab
ROCReceiver operating characteristic
SAE, SAEsSerious adverse event
SCSubcutaneous
SCFStem cell factor
sCSUStandalone chronic spontaneous urticaria
SDStandard deviation; symptomatic dermographism
SDCSmallest detectable change
SE, SEsStandard error
SF-6DShort Form 6-Dimension
sgAH, sgAHsSecond-generation antihistamine
sgH1-AHSecond-generation H1-antihistamine
SG-H1AHsSecond-generation H1-antihistamines
Siglec-8Sialic acid-binding immunoglobulin-like lectin 8
SOC, SoCStandard of care
T1R3Taste receptor type 1 member 3
TEAE, TEAEsTreatment-emergent adverse event
TKIsTyrosine kinase inhibitors
TNF-αTumor necrosis factor-alpha
TP1, TPsTreatment period 1; treatment periods
TPOThyroid peroxidase
TSHThyroid-stimulating hormone
UASUrticaria Activity Score
UAS7, UAS7sWeekly Urticaria Activity Score (sum of daily scores over 7 days)
UAS7TDWeekly Urticaria Activity Score from twice-daily assessments of itch and hives
UCAREUrticaria Centres of Reference and Excellence
UCTUrticaria Control Test
UCT7Urticaria Control Test, 7-day recall
UKUnited Kingdom
US, U.S.United States
USAUnited States of America
UTI, UTIsUrinary tract infection
V1, V18Version 1, version 18 (ClinicalTrials.gov record history)
VATValue-added tax
vs, vs.Versus
W48, W52, W76Week 48, Week 52, Week 76
w4IgETotal IgE 4 weeks after the start of treatment
WACWholesale acquisition cost
WBCWhite blood count
WKWeek
WTWild-type
WTPWillingness to pay
YTEM252Y/S254T/T256E Fc substitutions